120 related articles for article (PubMed ID: 9854498)
1. Steroid receptor concentrations as a prognostic factor in atypical endometrial hyperplasia.
Lindahl B; Willén R
Anticancer Res; 1998; 18(5B):3793-5. PubMed ID: 9854498
[TBL] [Abstract][Full Text] [Related]
2. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometry as a prognostic method for the identification of adenomatous hyperplasia at risk of developing endometrial carcinoma.
Lindahl B; Willén R
Anticancer Res; 1998; 18(6B):4611-2. PubMed ID: 9891527
[TBL] [Abstract][Full Text] [Related]
4. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
[TBL] [Abstract][Full Text] [Related]
5. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological analysis in cases with glandular and atypical glandular hyperplasia treated with gestagens].
Ivanov S
Akush Ginekol (Sofiia); 2005; 44(4):18-20. PubMed ID: 16028373
[TBL] [Abstract][Full Text] [Related]
7. [Modern tendencies in treatment of atypical glandular hyperplasia--our and foreign experience].
Ivanov S; Kovachev E; Tsonev A; Abbud A
Akush Ginekol (Sofiia); 2010; 49(2):47-9. PubMed ID: 20734678
[TBL] [Abstract][Full Text] [Related]
8. [Young women with atypical endometrial hyperplasia or endometrial adenocarcinoma stage I: will conservative treatment allow pregnancy? Results of a French multicentric survey].
Le Digabel JF; Gariel C; Catala L; Dhainaut C; Madelenat P; Descamps P
Gynecol Obstet Fertil; 2006 Jan; 34(1):27-33. PubMed ID: 16406735
[TBL] [Abstract][Full Text] [Related]
9. [Expressions of aromatase protein and sex hormone receptor in endometrial lesions].
Ma XX; Zhang SL; Gao S; Lu JM; Dong F
Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):395-8. PubMed ID: 16831363
[TBL] [Abstract][Full Text] [Related]
10. [Effect of gestagen therapy on clinical and biochemical parameters in patients with atypical endometrial hyperplasia].
Makarov OV; Sergeev PV; Sviridov NK; Kareva EN; Isaeva EG; Mgdesian KK; Kirpichnikova NV
Vopr Onkol; 2000; 46(5):570-3. PubMed ID: 11202189
[TBL] [Abstract][Full Text] [Related]
11. [Value of steroid receptors assessment in atypical endometrial hyperplasia].
Teleman S; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):813-6. PubMed ID: 14756025
[TBL] [Abstract][Full Text] [Related]
12. [p53 and steroid receptors support double endometrial carcinogenesis].
Teleman S; Mihailovici MS; Hilgarth M; Freudenberg N; Bettendorf H
Rev Med Chir Soc Med Nat Iasi; 1999; 103(3-4):131-5. PubMed ID: 10756939
[TBL] [Abstract][Full Text] [Related]
13. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
14. Steroid receptors in normal, hyperplastic and malignant human endometria.
Vihko R; Jänne O; Kauppila A
Ann Clin Res; 1980 Oct; 12(5):208-15. PubMed ID: 7015983
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma.
Sutter C; Dallenbach-Hellweg G; Schmidt D; Baehring J; Bielau S; von Knebel Doeberitz M; Gebert J
Int J Gynecol Pathol; 2004 Jan; 23(1):18-25. PubMed ID: 14668545
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous endometrial hyperplasia. A prospective, 5 year follow-up of 246 patients after abrasio only, including 380 patients followed-up for 2 years.
Lindahl B; Willén R
Anticancer Res; 1994; 14(5B):2141-6. PubMed ID: 7840513
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous endometrial hyperplasia. The prognostic significance of steroid receptor concentration. A two year follow-up of patients treated with abrasio only.
Lindahl B; Fernö M; Norgren A; Willen R
Anticancer Res; 1991; 11(5):1875-7. PubMed ID: 1768058
[TBL] [Abstract][Full Text] [Related]
18. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
Rubatt JM; Slomovitz BM; Burke TW; Broaddus RR
Gynecol Oncol; 2005 Nov; 99(2):472-6. PubMed ID: 16099019
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of nuclear receptor corepressor (NCoR) in progestin-induced growth suppression of endometrial hyperplasia and carcinoma.
Kashima H; Horiuchi A; Uchikawa J; Miyamoto T; Suzuki A; Ashida T; Konishi I; Shiozawa T
Anticancer Res; 2009 Apr; 29(4):1023-9. PubMed ID: 19414341
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous endometrial hyperplasia. A 5 year follow-up of 82 patients after high-dose gestagen treatment.
Lindahl B; Willén R
Anticancer Res; 1994; 14(6B):2831-4. PubMed ID: 7872726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
